Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Have you seen Dr MJ
Disclosure of interest: FAM, KG, VR, MK, WNW, KB, PH have nothing to disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P1005 - ESOC25-1187 PREVALENCE AND OUTCOME OF CEREBRAL MICROBLEEDS IN ANTIPHOSPHOLIPID SYNDROME Jonathan Naftali 1 , Rani Barnea 1 , Ruth Eliahou 1 , Tzippy Shochat 1 , Adi Wilf-Yarkoni 1 , Sivan Bloch 2 , Michael Findler 1 , Avi Leader 3 , Walid Saliba 2 , Eitan Auriel 1 1 Rabin medical center, Tel Aviv University, Petah Tikva, Israel, 2 Carmel medical center, Haifa, Israel, 3 Memorial Sloan Kettering Cancer Center, New-York, United States Background and Aims: Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by arterial and venous thrombosis
(zweryfikowany) W trakcie stosowania Monika M
But there have been serious injuries related to peptides
BPC-157 is not an FDA-approved drug, which means it is not available as a retail prescription product
US$ 22.90
US$ 20.62
US$ 21.68
US$ 25.94
US$ 27.23